ERFSF Stock Recent News

EUROFINS SCIENT (ERFSF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Eurofins Scientific is delivering a 10% growth without relying on exuberant COVID-related margins. The company boasts a robust business model, a significant market share, and a reliable and trustworthy management team. The stock has the potential to double by 2028 if the management projections are achieved.

Eurofins Scientific: The Normalization Of COVID-Related Sales Presents An Opportunity

Eurofins is dealing with a revenue decrease due to the lack of COVID testing and the sale of reagents. Excluding the COVID-related revenue, the H1 2023 revenue would have increased by a high single digit percentage. The company slightly reduced its 2023 FCF guidance to around 700M EUR but reconfirmed the 2027 guidance.

We present an overview of the testing, inspection, and certification (TIC) market. We highlight the different strategies that have been pursued by the main 4 players over time.

Eurofins Scientific SE (OTCPK:ERFSF) Q4 2022 Results Conference Call March 1, 2023 9:00 AM ET Company Participants Dr. Gilles Martin - Chairman and Chief Executive Officer Laurent Lebras - Chief Financial Officer Conference Call Participants Suhasini Varanasi - Goldman Sachs Shivani Gupta - HSBC Del Le Louet - SocieteGenerale Allen Wells - Jefferies James Rose - Barclays Dominic Edridge - Deutsche Bank Arthur Truslove - Citi Operator Ladies and gentlemen, welcome, and thank you for joining Eurofins' Full Year 2022 Results Call. Please note that this call is being recorded and will be available later for replay on the Eurofins Investor Relations website.

Eurofins Scientific printed cash during the COVID pandemic as its testing capacity was running at full utilization. There shouldn't be any massive post-COVID blues as growth in other domains should offset the decreasing COVID-related revenue.